Mineralys Therapeutics, Inc.
MLYS
Positions held
Your positionsMLYS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Mineralys Therapeutics operates in the biotechnology sector, which is known for its potential high returns due to innovative therapies and treatments.
- The company's market cap stands at approximately $1.94 billion, indicating a significant valuation in the biotech space.
- Despite current challenges, the target mean price for MLYS is $48.5, suggesting potential upside from its current trading levels.
- Mineralys Therapeutics has not generated any revenue, which raises concerns about its sustainability and operational viability.
- The company reported a net income loss of -241.071 million in Q2 2026, reflecting ongoing financial struggles.
- The stock has a 'Strong Sell' signal with a score of -24.00, indicating bearish sentiment among analysts and investors.
Fundamentals
| Market cap | $1.98B | Enterprise value | $1.41B | Trailing P/E | — | Forward P/E | -8.95 |
| PEG | — | Price / book | 3.59 | Beta | 0.69 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -80.9% | ROA | -46.2% | Debt / equity | 0.18 |
| Current ratio | 34.46 | Free cash flow | -$203.46M | Analyst recommendation | none | Mean target | $48.50 |
| 52w high | $47.65 | 52w low | $21.46 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$241M | -$39.3M | -$32.2M | -$36.9M | -$43.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$246M | -$45.3M | -$38.3M | -$41.1M | -$46.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$155M | -$178M | -$71.9M | -$29.8M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$171M | -$192M | -$84.7M | -$31.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-09-28 · Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat Data
2026-09-24 · Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
2026-09-21 · Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-09-09 · Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-08-26 · Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
2026-08-18 · Mineralys (MLYS) Q2 2026 Earnings Call Transcript
2026-08-13 · Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2026-08-12 · Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...
Price (daily)
Full chart · RSI · MACD · patterns